Subject index of Volume 124 · 1996

A 68930 40
Acetylcholinesterase inhibitor 347
Acute 159
Addiction 365
α_2-Adrenoceptor antagonists 347
ADRS 373
Adynamic ileus 288
Agranulocytosis 201
AIMS 373
Akathisia 188
Aldosterone 380
Alzheimer's disease 347
Aminoglutethimide 380
Amitriptyline 241
Amphetamine 219
Anaesthesia 288
Antinociception 365
Antipsychotic 159
Antipsychotic drugs 57
Antipsychotics 74
Anxiety 245, 355
Apomorphine 219, 231
Attention 261
Atypical 159
Atypical antipsychotic 50, 87
Atypical antipsychotic drug 2
Atypical antipsychotic drugs 148
Atypical antipsychotics 40
Autonomic dysregulation 226
Autoradiography 57
Behavioral sensitization 219, 279
Benzodiazepines 245
Biogenic amines 2
BNTX 211
Brain lithium concentration 275
BZ-1 (ω_1) receptor 245
Cannabinoids 315
Catalepsy 2
CCK-4 355
CCK-8s 355
CGP 37849 380
Chloral hydrate 288
Clomipramine 267
Clonidine 95
Clozapine 2, 40, 50, 126, 134, 148, 176, 188, 197, 201
Clozapine-*N*-oxide 197
Cocaine 219, 279, 300, 306
Cognition 255
Cognitive enhancement 323
Conditioned place preference 211
Conditioning 365
Context-dependency 300
Convulsions 300
Corticosterone 380
Cotinine 282
CP-88,059-1 141
^{11}C-Raclopride 141
Cutaneous microcirculation 241
D_3 receptors 231
d-Amphetamine 50
Delayed acute effect 323
Depression 267
Devazepide 355
Diazepam 355
Discrimination 306
Dopamine 35, 50, 87, 134, 176, 205, 231, 293
Dopamine antagonist 87
Dopamine D_1 and D_2 receptors 211
Dopamine D_2 receptors 141, 148
Dopamine "D_1-like" and "D_2-like" receptors 40
Dopamine receptor 2
Dopamine receptors 154, 306
Dopamine reuptake blockers 300
Dopamine-D_2-receptor 285
Dosing schedule 275
Double-blind 159
Drug cue 365
Drug discrimination 315, 340
Drug relapse 205
Drug self-administration 279
Electrophysiology 50
Elevated plus-maze 245
Eosinophilia 201
Epoxymexrenone 380
Equithesin 288
Ethanol 293, 340
Ethological analysis 355
Excitatory amino acid antagonist 261
Extrapyramidal side effects 134, 188
Extrapyramidal symptoms 2, 35, 168
Fatigue 226
Fenfluramine 95, 107
FG 7142 293
Fixed consecutive number 315
Fluoxetine 241
Frontal cortex 74
Genetics 332
Glucose 255
Glutamate 380
Grooming 40
Haloperidol 2, 126, 134, 201
5-HT_{1D} receptors 377
5-HT_{2A} receptor 107
3α-Hydroxy-5α-pregnan-20-one 340
Hypermotility 117
ICI 204,636 40
Inspiratory gasp response 241
Instrumental assessment 373
Interoception 365
Intravenous 365
(+)1-4-Iodo-2,5-dimethoxyphenyl-2-aminopropane, DOI 107
^{123}Iodobenzamide ([^{123}I]IBZM) 285
L-365,260 355
Laser Doppler flowmetry 241
Limbic dopamine 117
Lithium 275
Lithium-7 magnetic resonance spectroscopy 275
Locomotor activity 231, 245
Manic-depressive disorder 275
MAO inhibitors 226
MDL 100,907 107
Memory 255, 261
Memory facilitation 380
Memory impairment 380
Metabolism 255
3,4-Methylenedioxymethamphetamine, MDMA 95, 107
Mice 355
Microdialysis 74, 293
Monkeys 340
Morphine 293
Morris water maze 126
Mouse 219
Muscarinic 87
Naloxone 205
N-Desmethylclozapine 197
N-Ethyl-3,4-methylenedioxymethamphetamine, MDEA 95
Neuroactive steroids 340
Neuroleptics 134, 154, 168, 188
Neurosteroids 340
Neutropenia 201
Nicotine 282, 293, 323, 332
Nicotine-"compensation" hypothesis 282
Nicotinic receptor up-regulation 323
NMDA receptor 261
NMDA-receptor blocker 380
Nonhuman primates 134
NTB 211
Nucleus accumbens 74, 293
7-OH-DPAT 231, 306
Olanzapine 40, 50, 87, 126, 148, 159
Opiates 205
Opioid 365
Opioid receptors 211
Oxygen 255
Parkinsonism 35, 188
p-Chloroamphetamine, PCA 95
PD135158 355
Pentobarbital 340
Pentobarbitone 288
Pentylentetrazole 293
PET 35, 154
Pharmacokinetics 141
Picrotoxin 293
Pigeon 315
Placebo 159, 168
Plasma levels 197
Plus-maze 355
Positron emission tomography 141
PPHT 219
Prefrontal cortex 293
Prepulse inhibition 95, 107
Progressive-ratio 231
Prolactin 285
Psychosis 176
Quinpirole 231, 306
Raphe neurons 267
Rat 231, 245, 315, 347
Rating scale 373
Rats 117, 279
Receptor occupancy 57
Receptors 35
Reinforcement 211, 332
REM sleep deprivation 267
Response-reinstatement 205
Reverse tolerance 300
Review 2
Reward 117
Rhesus monkeys 306

Risk assessment 245
Risperidone 57, 126, 134
Routes 365
Schizophrenia 2, 35, 50, 95, 107, 154, 159, 168, 176, 188
Seizures 332
Self-administration 205, 332
Self-stimulation 231
Sensitization 365
Sensorimotor gating 95, 107
Seroquel 126
Serotonin 35, 87, 95, 107, 134, 176, 377
Sertindole 126, 134, 168
Sex 197
Single photon emission computed tomography (SPECT) 285
Single photon emission tomography 148
Spatial learning 126
SR141716A 315
SSRIs 377
Startle 315
Stereotypies 231
Steroids 380
Striatum 74
Sumatriptan 377
Sympathetic 226
Tardive dyskinesia 2, 188, 373
Tolerance 365
Vacuous chewing 40
Variability 373
Water maze 323
Wistar rats 95, 107
Within-session 365
Zimelidine 267
Ziprasidone 126, 141